

**Adherence to Antipsychotic Medications for Individuals with Schizophrenia**

CBH is committed to ensuring members receive quality care. Monitoring adherence to medications is one such way to improve quality of care. Members with a diagnosis of schizophrenia spectrum and psychotic disorders require adherence to medications for adequate symptom and disease management. Adherence to antipsychotic medications may reduce psychiatric morbidity and cost of care. Providers play a crucial role in supporting members’ adherence to medications.

*NCQA Reference: [ncqa.org/hedis/measures/adherence-to-antipsychotic-medications-for-individuals-with-schizophrenia/](https://www.ncqa.org/hedis/measures/adherence-to-antipsychotic-medications-for-individuals-with-schizophrenia/)*

*CDC Reference: [cdc.gov/mmwr/volumes/66/wr/mm6645a2.htm](https://www.cdc.gov/mmwr/volumes/66/wr/mm6645a2.htm)*

**Best Practices**

- ➔ Assess members’ adherence at each visit. Use a tool such as the MARS adherence questionnaire\* at each visit.
- ➔ Ensure member has an adequate supply of medications and refills.
- ➔ Share the CBH Antipsychotic Medication Guide\* with your members.
- ➔ Address members’ specific barriers to antipsychotic adherence. Refer to the PA DHS Preferred Drug List\* to see which medications are preferred.
- ➔ Assess if member is a candidate for a long-acting injectable antipsychotic to improve adherence. Refer to the CBH Long-Acting Injectable (LAI) Antipsychotic Medications webpage\*.
- ➔ Engage in shared decision making such that members are at the center of care. Learn more about shared decision-making at SAMHSA’s Provider Workbook\*.
- ➔ Collaborate with the member’s primary care physician.

*\* Tools available in the Resources section*

**Diagnoses Associated With This Measure**

- ➔ [F20.0] Paranoid Schizophrenia
- ➔ [F20.1] Disorganized Schizophrenia
- ➔ [F20.2] Catatonic Schizophrenia
- ➔ [F20.3] Undifferentiated Schizophrenia
- ➔ [F20.5] Residual Schizophrenia
- ➔ [F20.81] Schizophreniform Disorder
- ➔ [F20.89] Other Schizophrenia
- ➔ [F20.9] Schizophrenia, Unspecified
- ➔ [F25.0] Schizoaffective Disorder, Bipolar Type
- ➔ [F25.1] Schizoaffective Disorder, Depressive Type
- ➔ [F25.8] Other Schizoaffective Disorders
- ➔ [F25.9] Schizoaffective Disorder, Unspecified

**HealthChoices Preferred Drug List**

***First-Generation Antipsychotics:***

Chlorpromazine Hydrochloride, Fluphenazine Hydrochloride, Haloperidol, Loxapine, Molindone Hydrochloride, Prochlorperazine, Thioridazine, Thiothixene, Trifluoperazine

***Second-Generation Antipsychotics:***

Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone

**Adherence to Antipsychotic Medications for Individuals with Schizophrenia**

**Resources**

CBH Antipsychotic Medication Guide for Members  
[cbhphilly.org/wp-content/uploads/2021/01/CBH\\_Pharma\\_OneSheet\\_Antipsych\\_2020-08.pdf](http://cbhphilly.org/wp-content/uploads/2021/01/CBH_Pharma_OneSheet_Antipsych_2020-08.pdf)

CBH Medication Wallet Card for Members  
[cbhphilly.org/wp-content/uploads/2021/01/CBH\\_Pharma\\_WalletCard\\_2020-08.pdf](http://cbhphilly.org/wp-content/uploads/2021/01/CBH_Pharma_WalletCard_2020-08.pdf)

Pennsylvania Department of Human Services Statewide Preferred Drug List  
[papdl.com/sites/default/files/ghs-files/Penn%20Statewide%20PDL%2001.05.21.pdf](http://papdl.com/sites/default/files/ghs-files/Penn%20Statewide%20PDL%2001.05.21.pdf)

SAMHSA Provider Workbook  
[antipsych.c4designlabs.net/#/page-400](http://antipsych.c4designlabs.net/#/page-400)

MARS Adherence Questionnaire  
[pub.basecase.com/EvGWaXTPrR/](http://pub.basecase.com/EvGWaXTPrR/)

Long-Acting Injectable (LAI) Antipsychotic Medications webpage  
[cbhphilly.org/cbh-providers/available-services/lai-antipsych/](http://cbhphilly.org/cbh-providers/available-services/lai-antipsych/)

NCQA: Comprehensive Diabetes Care (CDC)  
[ncqa.org/hedis/measures/comprehensive-diabetes-care/](http://ncqa.org/hedis/measures/comprehensive-diabetes-care/)

Centers for Medicare & Medicaid Services Measures Inventory Tool  
[cmit.cms.gov/cmit/](http://cmit.cms.gov/cmit/)

NCQA Letter: NCQA Supports Medicaid Behavioral Measure Reporting  
[ncqa.org/comment-letter/ncqa-supports-medicaid-behavioral-measure-reporting/](http://ncqa.org/comment-letter/ncqa-supports-medicaid-behavioral-measure-reporting/)

Centers for Disease Control and Prevention: All About Your A1C  
[cdc.gov/diabetes/managing/managing-blood-sugar/a1c.html](http://cdc.gov/diabetes/managing/managing-blood-sugar/a1c.html)

**Lab Coverage Information**

<i>Health Plan</i>	<i>Laboratory Provider</i>
Community Behavioral Health	Atlantic Diagnostics and Parkway Clinical Laboratories
Aetna Better Health	Quest Diagnostics
Health Partners Plans	Quest Diagnostics
Keystone First	LabCorp
United Healthcare	LabCorp and Quest Diagnostics

**Disclaimer:** The information contained in this tip sheet is for educational and informational purposes only. The clinical services described in this tip sheet may not be covered for all CBH enrollees. To find out about what services are available to you under the CBH benefit package, please contact CBH Provider Operations at 215-413-3100.

*This document was developed in partnership with collaborating providers and the Southeastern Pennsylvania Medicaid MCOs that participate in the HealthChoices and Community HealthChoices programs.*